Brief: Context Therapeutics Reports Data From Mid-stage Study Of Uterus Cancer Drug
06/02/2023 15:46
Feb 6 (Reuters) - Context Therapeutics Inc CNTX.O :
* CONTEXT THERAPEUTICS HIGHLIGHTS CLINICAL RESPONSES FROM
THE
PHASE 2 OATH CLINICAL TRIAL EVALUATING ONA-XR FOR THE TREATMENT
OF ENDOMETRIAL CANCER
* CONTEXT THERAPEUTICS - ONA-XR CONTINUES TO BE SAFE AND
WELL-TOLERATED
* CONTEXT THERAPEUTICS - ONA-XR INITIAL DATA SIGNALS
POSITIVE
CLINICAL ACTIVITY AND CONFIRMED TUMOR SHRINKAGE
* CONTEXT THERAPEUTICS - UPDATED DATA REGARDING PHASE 2 OATH
TRIAL
IS EXPECTED TO BE PROVIDED IN Q2 2023
Source text for Eikon: ID:nGNX7cYPbY
Further company coverage: CNTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202